5-amino-1MQ
Also: 5-amino-1-methylquinolinium, 5A1MQ
4 papers: 3 animal studies, 1 review or preprint.
Legal status as understood on this date. Listed, not endorsed. How we list.
Summary
5-amino-1MQ is not a peptide. It is a small molecule that inhibits nicotinamide N-methyltransferase, an enzyme that sits between cellular metabolism and the regulation of gene activity. It is a research compound with no published human data at all, and it is on this site because listed suppliers sell it alongside peptides.
What it targets
The enzyme this compound blocks methylates nicotinamide using the body's universal methyl donor, which links one-carbon metabolism to NAD+ levels; a 2024 review describes how differently it behaves across tissues and surveys its reported roles in cancer, liver, brain, lung, cardiovascular and kidney disease, which is a reason to expect effects beyond fat tissue. The most direct evidence for the compound itself is a 2024 study in which mice made obese on a high-fat diet received it daily for 28 days: the authors report dose-dependent limits on body weight and fat gain, better glucose tolerance and insulin sensitivity, lower insulin levels and reduced fatty-liver changes, alongside measurements of how the compound behaves after intravenous, oral and subcutaneous administration. Earlier work validated the enzyme as a target, including a related inhibitor whose effects disappeared in mice lacking the enzyme. Every result above is in mice or cells.
Clinical Research
Suppliers stocking 5-amino-1MQ
25 of the 49 listed suppliers. Each row opens its full listing.